Douglas Falk

Doug Falk, MS, is a Venture Partner at Riptide Ventures. In addition to this, he co-founded and joined Vita Therapeutics, Inc. as Chief Executive Officer in 2019. Prior, he spent six years in the investment world with a particular focus in biotechnology at Brown Advisory, where he was a principal, Merrill Lynch, and Lazard. He was also involved in the formation of Regron Therapeutics, a Johns Hopkins spin, and currently sits on the board of directors. In addition to his work at Riptide Ventures, Doug is also a venture partner at Sunday Ventures. He received his MS from Johns Hopkins University in biotechnology and his BA from Goucher College in economics and business management